Kairos Pharma, Ltd. (KAPA) Stock Score, Valuation & Financial Research

Kairos Pharma, Ltd. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for KAPA

Kairos Pharma, Ltd. does not currently have a complete Wall Street Score. The stored market price is USD 1.59. These figures are a research snapshot, not a buy or sell recommendation.

What Kairos Pharma, Ltd. does

Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Kairos Pharma is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on advancing drug candidates through clinical trials, supported by research grants and capital raises, with the goal of eventually commercializing therapeutics for cancer.

Products and services

  • The company develops a pipeline of five pre-clinical or clinical-stage drug candidates, including antibodies and small molecules, designed to treat prostate, lung, and breast cancers, as well as glioblastoma.

Customer types

Cancer patients.

Suppliers, materials and equipment

  • Drug manufacturer — The company relies on third-party manufacturers for the supply of its drug candidates; the specific supplier company is unnamed. Source

Business relationships and partnerships

  • Cedars-Sinai Medical Center — The company holds an exclusive license agreement with Cedars-Sinai Medical Center for certain therapeutic assets. Source

Business strengths to evaluate

  • Pipeline of five pre-clinical or clinical-stage drug candidates Source

Business risks and research considerations

  • Dependence on third-party drug supply Source
  • Clinical trial enrollment and execution risks Source

Sources: Company research source · Cedars-Sinai Medical Center · Drug manufacturer · Pipeline of five pre-clinical or clinical-stage drug candidates

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

KAPA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.59
Market capitalization:
4.86M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -5.81M
Free cash flow:
USD -3.44M
Cash:
USD 2.63M
Total debt:
USD 0.00
EPS:
USD -1.94

What stands out

  • Free cash flow is USD -3.44M, negative for the stored period.
  • The balance sheet shows USD 2.63M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 2.63M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for KAPA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can KAPA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is KAPA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for KAPA to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of KAPA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research KAPA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.